您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Fenspiride
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Fenspiride
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
CAS NO:5053-06-5
包装与价格:
包装价格(元)
5 mg电议
50 mg电议
100 mg电议

产品介绍
Fenspiride 是 H1-组胺受体的拮抗剂。 Fenspiride 是一种具有口服活性的非甾体类抗炎药,可用于治疗呼吸道感染和中耳炎。 Fenspiride 抑制磷酸二酯酶 4 和磷酸二酯酶 3 的活性,-logIC50 值分别为 4.16+/-0.09 和 3.44+/-0.12。 磷酸二酯酶 5 活性也受到抑制,-logIC50 值约为 3.8。

产品描述

Fenspiride is an antagonist of H1-histamine receptors. Fenspiride is an orally active non-steroidal anti-inflammatory agent that can be used for the treatment of respiratory tract infections and otitis media. Fenspiride inhibited phosphodiesterase 4 and phosphodiesterase 3 activities with -logIC50 values of 4.16+/-0.09 and 3.44+/-0.12, respectively. Phosphodiesterase 5 activity was also inhibited with a -logIC50 value of approximately 3.8.

体外活性

Fenspiride (approximately 100 μM) inhibits histamine-induced tracheal constriction in the isolated guinea pig. Fenspiride (< or = 10(-3) M) produced less than 25% inhibition of phosphodiesterase 1 and phosphodiesterase 2 activities [2].

体内活性

Administered orally at 60 mg/kg for 3 days, Fenspiride reduced the lipopolysaccharide-induced early rise of tumor necrosis factor concentrations in serum (4.2 + 0.9 vs. 2.3 + 0.5 ng/ml, P< 0.05) and in the bronchoalveolar lavage fluid (55.7 + 20 vs. 19.7 + 7.5 ng/ml, P< 0.05) of the model of endotoxemia that also reduced the lipopolysaccharide-induced primed stimulation of alveolar macrophages [3]. Administered orally at 60 mg/kg for 3 days, Fenspiride reduced the increased serum concentrations of extracellular type II phospholipase A 2, the intensity of the neutrophilic alveolar invasion, and the lethality due to the lipopolysaccharide [3].

Cas No.

5053-06-5

分子式

C15H20N2O2

分子量

260.33

储存和溶解度

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years